Histone deacetylases (HDACs) are attractive therapeutic targets, and selective HDAC inhibitors (HDACi), alone or in combination with other anti-cancer agents, are promising treatment strategies in multiple myeloma (MM). [1] [2] [3] [4] To date, however, the effect of HDACi on immune regulation in the MM bone marrow (BM) microenvironment, as well as the therapeutic potential of combining selective HDACi with immune-based therapies, is undefined. Recent studies showed that besides histone modification, HDACs also modulate non-histone targets including immune regulatory molecules. 5, 6 For example, blockade of HDACs upregulates immunecheckpoints such as PD-1 ligand (PD-L1). 6 Moreover, the combination of HDACi with PD-1/PD-L1 checkpoint blockade significantly improves immunotherapy in a murine B16F10 model. 6 In MM, PD-L1 expression directly correlates with progression of disease, with highest levels in patients with relapsed/ refractory MM. 7, 8 Here, we utilized an orally bioavalable HDAC6 selective inhibitor ACY-241, currently in clinical trials, 9 to examine whether the combination of ACY-241 with anti-PD-L1 antibody enhances anti-MM immunity in the MM BM microenvironment.
For our studies, we utilized a co-culture model of immune effector cells (plasmacytoid dendritic cells (pDCs), T cells, NK cells) and MM cells. 7, 10 Specifically, we have identified that interactions of MM cells with innate and adaptive immune cells in the BM milieu confer immune suppression via PD-1/PD-L1 signaling axis (Figure 1a : Schema). 7, 10 This is exemplified in our studies demonstrating a novel functional interaction between pDCs (Lin
) and MM cells, implicating pDCs in both MM pathogenesis and immune suppression. We showed that increased numbers of pDCs are present in MM patient BM versus normal BM. Importantly, pDCs in MM BM are relatively resistant to current therapies; protect tumor cells from therapy-induced cytotoxicity; promote tumor growth and survival; and confer immune dysfunction. 7, 10 Using our coculture model, we further delineated the immunosuppressive mechanism(s) that have a role during pDC-T-NK cell interactions with tumor cells. Specifically, we found that: (1) MM cells and pDCs expressed high surface levels of PD-L1, whereas T cells showed high PD-1 levels; and (2) PD-L1 on MM pDCs suppresses PD-1 expressing T-cell and NK cell immune function; and (3) blockade of PD-L1-PD-1 signaling axis by anti-PD-L1 Ab generates MM-specific CD8+ ctotoxic T lymphocyte (CTL) activity, as well as enhances NK cell-mediated MM cell cytolytic activity. Importantly, our co-culture Accepted article preview online 6 November 2017; advance online publication, 5 January 2018 Letters to the Editor model allows for evaluation of the effect of anti-MM drugs on immune regulatory molecules expressed on immune cells and tumor cells, as well as provides a platform for validating all immune-based combination strategies, especially in the context of immune cells within the MM BM microenvironment. In the current study, we utilized these models to specifically examine whether the combination of ACY-241 with anti-PD-L1 Ab increases antitumor immunity and cytotoxicity in MM. We first evaluated whether the combination of ACY-241 and anti-PD-L1 Ab enhances MM patient NK cell-mediated cytolytic activity. For these studies, we utilized low concentration of ACY-241 that do not significantly affect the viability of pDCs, T cells or NK cells (Supplementary Figure 1 A-C) . Freshly isolated NK cells from MM patient BM (n = 7) were co-cultured with autologous pDCs in the presence of anti-PD-L1 Ab (5 μg/ml), ACY-241 (0.2 μM) or ACY-241 plus anti-PD-L1 Ab for 5 days. Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells prestained with Celltrace violet for 24 h, followed by 7-AAD staining and quantification of MM cell lysis by flow cytometry. The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust NK cell-mediated cytotlytic activity against MM cells than either agent alone (Figure 1b and c) . No significant NK cellmediated cytotoxicity was noted in the absence of pDCs in these experiments (Supplementary Figure 2B) , confirming a key role of pDCs in NK cell functioning in response to treatment with ACY-241 and/or anti-PD-L1 Ab. To further confirm our findings, we next performed analysis of CD107a as a marker of NK cell function. MM patient pDCs and autologous NK cells were treated with ACY-241, anti-PD-L1 Ab or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to assess surface CD107a expressing CD3 − /CD56 + NK cells by multi-parameter flow cytometry. In concert with our finding shown in Figures 1b and c 
, ACY-241 plus anti-PD-L1 Ab increases CD107a
+ degranulated cytolytic NK cells (Supplementary Figure 3) .
As in our prior study, 7 anti-PD-L1 Ab alone restored NK cellmediated anti-MM activity. Interestingly, treatment of pDC-NK cells co-cultured with ACY-241 alone triggerred NK cell cytolytic activity against MM cells (Figures 1b and c) . In this context, a recent study showed a role of HDAC6 in the regulation of PD-L1 in melanoma. 11 We hypothesized that ACY-241 may downregulate PD-L1/PD-1-mediated NK cell immune suppression during pDC-NK cell interactions. Indeed, ACY-241 significantly decreases PD-L1 expression on pDCs (Supplementary Figure 5) , which in turn attentuates PD-L1/PD-1-mediated NK suppression and thereby enhances NK cell-mediated MM cell cytotoxicity. Although not examined here, other possibilities may account for ACY-241 activity. Similar to immunomodulatory agent Lenalidomide, ACY-241 may skew effector cytokine (IFN-γ; TNFα) production toward enhancing NK cell anti-MM activity. Alternatively, ACY-241 may act as reported for HDACi LBH589, which upregulates activation marker CD69 on NK cells. 12 Finally, ACY-241 may enhance NK cell anti-MM activity by altering receptor-ligand (for example, NKG2D or KIR) expression-mediated tumor cell killing. These issues remain to be examined. Nonetheless, we here show that: (1) pDC-MM cell interactions modulate NK cell cytotoxic activity; (2) combined ACY-241 and anti-PD-L1 Ab enhances MM patient pDC-induced NK cell-mediated cytolytic activities against autologous MM cells; (3) ACY-241 or anti-PD-L1 alone have the ability to stimulate NK cell effector function, albiet to a lesser extent than in combination; and (4) ACY-241 is an immunemodulating agent as it triggers significant NK cell anti-MM activity.
A recent study showed that a HDAC6i ricolinostat triggers T-cell activation and APC function. 13 We therefore next examined whether ACY-241, anti-PD-L1 or their combination triggers the generation of MM-specific CTLs ex vivo. MM patient BM CD8 + T cells (n = 7) were co-cultured with autologous pDCs (pDC: T; 1:10 ratio) in the presence of anti-PD-L1 Ab, ACY-241 or ACY-241 plus anti-PD-L1 Ab for 5 days. Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells that were prestained with CellTracker Green for 24 h, followed by 7-AAD staining and quantification of CTLs-mediated MM cell lysis by FACS. The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust autologous MM-specific CD8 + CTL activity than either agent alone, evidenced by decreased number of viable CellTracker Green-positive MM cells (Figure 2a and Supplementary Figure 4) . MM cells were also cultured alone without immune effector cells for the same time period, and data obtained from flow analysis were used for normalization to account for the spontaneous MM cells death. We next performed CD107a degranulation assays to confirm the generation of CD8 + T-cell cytolytic activity. MM patient pDCs were co-cultured with autologous T cells and treated with ACY-241, anti-PD-L1 Ab, or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to measure CD107a on the cell surface of activated CD3 + /CD8 + T cells using flow cytometry. In agreement with our findings from CTL assays (Figure 2a and Supplementary Figure 4) , a more robust increase in surface CD107a + cytotoxic T cells was noted upon treatment with combined ACY-241 and anti-PD-L1 Ab versus either ACY-241 or anti-PD-L1 Ab alone (Figure 2b) . No significant MM patient CTL activity was noticed in the absence of pDCs (Supplementary Figure 2C) .
Collectively, our data show that combination of selective HDAC6 inhibitor ACY-241 with anti-PD-L1 Ab triggers both CTLsand NK cells-mediated MM cell killing ( Supplementary Figures 6  and 7 ; Schema). Mechanistic studies show that combined activity of ACY-241 and anti-PD-L1 is due to downregulation of immunosuppressive PD-L1/PD-1 signaling during pDC-T cells and pDC-NK cells interactions. It is likely that besides blockade of PD-L1/PD-1, this combination regimen also abrogates other immunosuppressive mechanisms and/or activates immuneactivating pathways among pDCs, NK or T cells that together contribute in restoration of anti-MM immunity. Ongoing studies are focused on investigating these immune mechanism(s).
Finally, recent data indicate potential toxicity associated with checkpoint inhibitors in MM. However, in contrast to inhibitor of checkpoint PD-1 (pembrolizumab), clinical trials of anti-PD-L1 Abs to date show safety, without any significant adverse events in MM patients.
14 Moreover, a recent study found a better response rate in patients with higher PD-L1 levels on MM cells, and PD-1 expression on lymphocytes correlated weakly with progressionfree survival in a small subset of patients. 15 These findings, coupled with our data, support translation of combined ACY-241 and anti-PD-L1 Ab into clinical trials to restore immune function, enhance MM cytotoxicity and improve patient outcome in MM. Bruton's tyrosine kinase (BTK) is highly expressed and activated in more than 90% of acute myeloid leukemia (AML) cases.
CONFLICT OF INTEREST
1,2 An important contribution of BTK has been reported in the context of FLT3-ITD-positive AML 2 and is involved in signaling pathways of Toll-like receptors, 3 nuclear factor κB (NFκB) 2 and chemokine receptor CXCR4. 4 Expression and activation of BTK are associated with poor prognosis of AML patients. 2, 5 The mixed-lineage leukemia (MLL) gene is frequently disrupted by chromosomal rearrangements and is associated with distinct clinical features and poor prognosis. Human cord blood hematopoietic CD34+ progenitor cells transduced with MLL-AF9 (MA9) maintain a myelomonocytic AML-like phenotype in cytokine-supplemented medium. 6 The cells induce leukemia in non-obese diabetic/severe combined immunodeficiency mice representing a human model of MA9-positive leukemia. 6 The specific contribution of BTK in MLL-rearranged AML (MLL-AML) is not known. Because an essential role of NFκB signaling by MLL oncoproteins in the maintenance of leukemic stem cells was reported, 7 we investigated the contribution of BTK and p65 in MLL-rearranged leukemia.
Whole cell lysates from AML cell lines (Figure 1a (Figure 1c) . Activated p65 is reported to induce the expression of BTK in bortezomib-resistant multiple myeloma cell lines and primary malignant plasma cells. 8 That study indicated the presence of two p65-binding sites in BTK promoter region. These observations led us to investigate the involvement of activated p65 in regulating the expression of BTK. We performed luciferasebased BTK promoter assays with empty (pGL4) or test construct (pGL4-BTK). MOLM-13 and MA9.3 cells electroporated with pGL4-BTK vector revealed substantially elevated luciferase activity demonstrating the transcriptional activity of p65 (Supplementary Figure 2A, left panel) . Interestingly, ibrutinib treatment suppressed BTK promoter activity in these cell lines (Supplementary Figure 2A 
